Inflammation and Pain Post Cataract Surgery Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | Oculis, Formosa Pharmaceuticals, Inc., Xigen

DelveInsight's "Inflammation and Pain Post Cataract Surgery Market Insights, Epidemiology, and Market Forecast- 2034" report delivers an in-depth understanding of the Inflammation and Pain Post Cataract Surgery, historical and forecasted epidemiology as well as the Inflammation and Pain Post Cataract Surgery market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover which therapies are expected to grab the Inflammation and Pain Post Cataract Surgery Market Share @ Inflammation and Pain Post Cataract Surgery Market Outlook- https://www.delveinsight.com/sample-request/inflammation-and-pain-post-cataract-surgery-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Inflammation and Pain Post Cataract Surgery Market Report
• In February 2025, The Eye Institute of West Florida announced a study will assess post cataract the efficacy and safety of two different FDA approved regimens, which include the standard of care (topical steroids, NSAIDs and antibiotics) or Intracameral Dexamethasone (DexycuTM) along with topical NSAIDs and antibiotics.
• In January 2025, Surface Ophthalmics Inc. announced a study is to see how well SURF-201 works and what side effects there are, and to compare it with Vehicle (placebo). This study will involve about 80 study participants at several different research sites in the United States.
• As per our analysis, in the US about 20 million Americans aged 40 years and older have cataracts in one or both eyes, and around 6 million have had their lens removed operatively. As per our analysis, chronic or recurrent inflammation, including cystoid macular edema, occurs in about 0.1% to 2% of patients following routine cataract surgery.
• As per analysis in 2019, 2,200 cataract surgeries were performed in the US. Of these cases, around 40 eyes had post-operative iritis lasting longer than 1 month.
• Based on our analysis, cataract surgery is the most commonly performed elective surgical procedure in the UK with around 330, 000 cataract operations performed per year in England alone.
• The increase in Inflammation and Pain Post Cataract Surgery Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Inflammation and Pain Post Cataract Surgery Market is anticipated to witness growth at a considerable CAGR.
• The leading Inflammation and Pain Post Cataract Surgery Companies such as Oculis, Formosa Pharmaceuticals, Inc., Xigen, and others.
• Promising Inflammation and Pain Post Cataract Surgery Pipeline Therapies such as APP13007, 0.05%, XG-102, Dexamethasone, SURF-201, Omidria, Clobetasol Propionate, and others.

Stay ahead in the Inflammation and Pain Post Cataract Surgery Therapeutics Market with DelveInsight's Strategic Report @ Inflammation and Pain Post Cataract Surgery Market Outlook- https://www.delveinsight.com/sample-request/inflammation-and-pain-post-cataract-surgery-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Inflammation and Pain Post Cataract Surgery Epidemiology Segmentation in the 7MM
The epidemiology section of Inflammation and Pain Post Cataract Surgery offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

Download the report to understand which factors are driving Inflammation and Pain Post Cataract Surgery Epidemiology trends @ Inflammation and Pain Post Cataract Surgery Prevalence- https://www.delveinsight.com/sample-request/inflammation-and-pain-post-cataract-surgery-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Marketed Inflammation and Pain Post Cataract Surgery Drugs
• DEXTENZA (dexamethasone): Ocular Therapeutix
DEXTENZA (dexamethasone) is the first US FDA-approved intracanalicular insert, a novel route of administration that delivers the drug to the surface of the eye without the need for eye drops. It is a preservative-free, resorbable hydrogel insert that delivers 0.4mg of dexamethasone to treat post-surgical ocular inflammation and pain for up to 30 days with a single administration. DEXTENZA (dexamethasone) originally received the US FDA approval in November 2018 for the treatment of ocular pain following ophthalmic surgery.

• INVELTYS (loteprednol etabonate ophthalmic suspension): Alcon
INVELTYS (loteprednol etabonate ophthalmic suspension) 1% is indicated for the treatment of post-operative inflammation and pain following ocular surgery. The mechanism of action of INVELTYS (loteprednol etabonate ophthalmic suspension) involves its function as a corticosteroid that inhibits the inflammatory response to various inciting agents. INVELTYS was approved by the US FDA in August 2018.

• APP13007 (clobetasol propionate): Eyenovia
APP13007 (clobetasol propionate) is the first product developed using Formosa's proprietary APNT nanoparticle formulation platform. When used for the treatment of post-operative inflammation and pain following ocular surgery, APP13007 acts by inhibiting edema, fibrin deposition, capillary dilation, leukocyte migration, and capillary proliferation associated with inflammation. APP13007 was approved by the US FDA in March 2024.

Emerging Inflammation and Pain post-cataract Surgery Drugs
• VVN461: VivaVision Biotech
VVN461 is a potent JAK1 immunomodulator independently developed by VivaVision Biotech, and there is increasing evidence showing that the JAK-STAT signaling pathway is essential for inflammation and immune response. VVN461 can inhibit multiple inflammatory cytokine pathways with high activity to treat postoperative inflammation of cataracts. The results of human pharmacokinetic studies showed that VVN461 ophthalmic solution had low exposure in plasma, indicating that VVN461 ophthalmic solution had a high safety profile due to low systemic toxicity while exerting local anti-inflammatory effects. VVN461 is under clinical development by VivaVision Biotech for the treatment of Inflammation and Pain Post Cataract Surgery.

• OCS-01: Oculis
Leveraging Oculis' proprietary OPTIREACH technology, OCS-01 is a novel, high-concentration (15 mg/ml), topical formulation of dexamethasone. The optireach solubilizing formulation technology addresses the main limitations of conventional eye drops by improving the solubility of lipophilic drugs, increasing the residence time on the eye surface and thereby, enabling less frequent administration for front-of-the-eye and the drug passage from the eye surface to the posterior segment for back-of-the-eye diseases. OCS-01 is a potential once-daily treatment for Post-cataract Surgery Inflammation. OCS-01, the first investigational eye drop designed for front- and back-of-the-eye, met both primary endpoints in the Phase 3 OPTIMIZE-1 trial with a once-daily regimen for treating inflammation and pain following cataract surgery. The trial results showed OCS-01's superiority in reducing inflammation and pain vs. vehicle as well as a favorable safety profile. OCS-01 is under clinical development by Oculis and is currently in phase III OPTIMIZE-2 trial for the treatment of inflammation and pain post cataract surgery..

Inflammation and Pain Post Cataract Surgery Treatment Market Landscape
The Inflammation and Pain Post Cataract Surgery treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Inflammation and Pain Post Cataract Surgery has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

To learn more about Inflammation and Pain Post Cataract Surgery treatment guidelines, visit @ Inflammation and Pain Post Cataract Surgery Treatment Market Landscape- https://www.delveinsight.com/sample-request/inflammation-and-pain-post-cataract-surgery-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Inflammation and Pain Post Cataract Surgery Market Outlook
Inflammation and pain are becoming common complications post-cataract surgery. Many researchers and industries are working to develop treatments for post-cataract surgery inflammation and pain. The combination of topical NSAIDs and corticosteroids appears to be the most effective approach to control post-cataract surgery inflammation and pain. If a patient is diagnosed with chronic or recurrent postoperative inflammation 6 to 8 weeks after cataract surgery, then the postoperative steroid is typically restarted. If the inflammation is severe, then dosing may be as frequent as every 2 hours for a few days before being tapered. If the inflammation is mild to moderate, then the steroid is administered four times per day.

Inflammation and Pain Post Cataract Surgery Drugs Uptake
The drug chapter of the Inflammation and Pain Post Cataract Surgery report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of Inflammation and Pain Post Cataract Surgery clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Inflammation and Pain Post Cataract Surgery.

Major Inflammation and Pain Post Cataract Surgery Companies
Oculis, Formosa Pharmaceuticals, Inc., Xigen, and others.

Learn more about the FDA-approved drugs for Inflammation and Pain Post Cataract Surgery @ Drugs for Inflammation and Pain Post Cataract Surgery Treatment- https://www.delveinsight.com/sample-request/inflammation-and-pain-post-cataract-surgery-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Inflammation and Pain Post Cataract Surgery Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Inflammation and Pain Post Cataract Surgery Companies- Oculis, Formosa Pharmaceuticals, Inc., Xigen, and others.
• Inflammation and Pain Post Cataract Surgery Pipeline Therapies- APP13007, 0.05%, XG-102, Dexamethasone, SURF-201, Omidria, Clobetasol Propionate, and others.
• Inflammation and Pain Post Cataract Surgery Market Dynamics: Inflammation and Pain Post Cataract Surgery Market Drivers and Barriers
• Inflammation and Pain Post Cataract Surgery Market Access and Reimbursement, Unmet Needs and Future Perspectives, Inflammation and Pain Post Cataract Surgery Clinical Trials

Discover more about Inflammation and Pain Post Cataract Surgery Drugs in development @ Inflammation and Pain Post Cataract Surgery Clinical Trials Assessment- https://www.delveinsight.com/sample-request/inflammation-and-pain-post-cataract-surgery-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Inflammation and Pain Post Cataract Surgery Executive Summary
3. Inflammation and Pain Post Cataract Surgery Competitive Intelligence Analysis
4. Inflammation and Pain Post Cataract Surgery: Market Overview at a Glance
5. Inflammation and Pain Post Cataract Surgery: Disease Background and Overview
6. Patient Journey
7. Inflammation and Pain Post Cataract Surgery Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Inflammation and Pain Post Cataract Surgery Unmet Needs
10. Key Endpoints of Inflammation and Pain Post Cataract Surgery Treatment
11. Inflammation and Pain Post Cataract Surgery Marketed Products
12. Inflammation and Pain Post Cataract Surgery Emerging Therapies
13. Inflammation and Pain Post Cataract Surgery: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Inflammation and Pain Post Cataract Surgery Market Outlook
16. Access and Reimbursement Overview of Inflammation and Pain Post Cataract Surgery
17. KOL Views
18. Inflammation and Pain Post Cataract Surgery Market Drivers
19. Inflammation and Pain Post Cataract Surgery Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

List of Top Selling Market Research Reports in 2025

ADHD Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
NK Cell Therapy Market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Indwelling catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Vital sign monitors devices market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
Cardiac implantable electronic devices market- https://www.delveinsight.com/report-store/cardiac-implantable-electronic-devices-cieds-market
HIP replacement devices market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Positive airway pressure device market- https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
Surgical robotic system market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
Thrombectomy devices market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Thyroid cancer market- https://www.delveinsight.com/report-store/thyroid-cancer-market
ly3454738 drug insight- https://www.delveinsight.com/report-store/moderate-to-severe-atopic-dermatitis-pipeline-insight
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Medical marijuana market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.